Fmr LLC Castle Biosciences Inc Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Fmr LLC holds 1,220 shares of CSTL stock, worth $37,039. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,220

Previous 872 39.91%

Holding current value

$37,039

Previous $19,000 36.84%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$18.84 - $24.94 $6,556 - $8,679	348 Added 39.91%	1,220 $26,000
Q1 2024 May 13, 2024	SELL	$18.06 - $25.3 $1,318 - $1,846	-73 Reduced 7.72%	872 $19,000
Q4 2023 Feb 13, 2024	SELL	$12.19 - $22.43 $792 - $1,457	-65 Reduced 6.44%	945 $20,000
Q3 2023 Nov 13, 2023	BUY	$13.28 - $20.3 $4,634 - $7,084	349 Added 52.8%	1,010 $17,000
Q2 2023 Aug 11, 2023	SELL	$11.66 - $26.0 $606 - $1,352	-52 Reduced 7.29%	661 $9,000
Q1 2023 May 11, 2023	SELL	$19.47 - $28.49 $1,187 - $1,737	-61 Reduced 7.88%	713 $16,000
Q4 2022 Feb 13, 2023	SELL	$18.08 - $30.0 $126 - $210	-7 Reduced 0.9%	774 $18,000
Q3 2022 Nov 10, 2022	BUY	$22.51 - $34.32 $5,042 - $7,687	224 Added 40.22%	781 $20,000
Q2 2022 Aug 12, 2022	BUY	$16.0 - $45.99 $1,696 - $4,874	106 Added 23.5%	557 $12,000
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $14,959 - $21,187	451 New	451 $20,000
Q4 2021 Feb 14, 2022	SELL	$39.06 - $67.58 $78 - $135	-2 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$60.13 - $77.6 $120 - $155	-2 Reduced 50.0%	2 $0
Q2 2021 Aug 13, 2021	BUY	$50.07 - $76.78 $200 - $307	4 New	4 $0

Others Institutions Holding CSTL

# of Institutions

171

Shares Held

25.5M

Call Options Held

511K

Put Options Held

130K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $798M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account